Physician profile
Richard Teter
NPI 1063973931
$2,281.84
in general payments reported to CMS, 2019-2025
10 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,136 · 2023: $553 · 2024: $146 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,225.40 | 2022-2025 | Variax, Ortholoc 3di, Augment Injectable |
| Acera Surgical, INC. | $258.91 | 2022-2023 | Restrata Wound Matrix |
| Kerecis Limited | $200.96 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Davol INC. | $164.67 | 2025 | Venovo |
| Heron Therapeutics, INC. | $124.97 | 2022 | |
| Novastep INC. | $114.82 | 2025 | Nexis |
| Grt US Holding, INC. | $102.24 | 2022 | |
| Organogenesis INC. | $36.35 | 2023 | Puraply |
| Paratek Pharmaceuticals, INC. | $28.29 | 2024 | Nuzyra |
| Sebela Pharmaceuticals INC. | $25.23 | 2023 | Naftin, Pramosone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Teter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.